botulinus toxin

Results The short-term effect of the botulinus toxin Type A injection treatment to blepharospasm and facial spasm was 92.7%, the half-year relapse rate was 58.3%, and there was no anaphylactic response or serious systemic adverse reaction.

结果应用A型肉毒毒素治疗特发性眼睑、面肌痉挛的短期有效率为97.2%，半年的复发率为58.3%，未见过敏反应及严重全身不良反应。

互联网摘选

Influential factors of the clinical function of botulinus toxin and the countermeasures

肉毒毒素临床作用的影响因素及对策

互联网摘选

Impact on Quality of Life of Botulinus Toxin A Injection for Hemifacial Spasm

A型肉毒毒素注射对偏侧面肌痉挛患者生存质量的影响

互联网摘选

Local injection of type A botulinus toxin is a novel therapy to treat child spasm dysmyotonia.

局部肌内注射A型肉毒毒素治疗儿童痉挛型肌张力障碍是一种新的治疗方法。

互联网摘选

Clinical Analysis of Botulinus Toxin A for Hemifacial Spasm

A型肉毒毒素治疗半侧面肌痉挛的临床疗效评价

互联网摘选

Botulinus toxin from a clostridium botulin fermentation broth was separated and purified by membrane filtration technology. To remove the bacteria from the fermentation broth, we chose a 0.65 μ m pore size microfiltration membrane, reaching a removal ratio of 100%.

报道了把膜分离技术应用于肉毒发酵液的纯化.用孔径为0.65μm的微滤膜对发酵液进行除菌，除菌率达到100%；

互联网摘选

Conclusion Botulinus toxin Type A is the first choice in treating blepharospasm and facial spasm, although its curative effect last for half a year, it is still a simple and effective treatment method.

结论A型肉毒毒素为治疗特发性眼睑、面肌痉挛首选药物，尽管其疗效半年左右，但仍不失为一种简单有效的治疗方法。

互联网摘选